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Corneal scarring is a third leading cause of global 
blindness, often caused due to injury, trauma, and/or infec-
tion to the eye [1]. No potent and safe therapeutic agents 
are currently available to treat corneal fibrosis, and corneal 
transplantation remains the only option to restore vision. The 
epithelial-stromal interaction in the cornea plays an important 
role in corneal wound healing following injury. To counter 
damage caused by trauma or injury, corneal epithelial and 
stromal cells release a wide variety of cytokines and growth 
factors [2-4]. Out of many cytokines, transforming growth 
factor β (TGFβ) has been identified as a key inducer of 
corneal fibrosis [5,6]. TGFβ has been shown to activate both 
Smad-dependent and Smad-independent pathways, such as 
the mitogen-activated protein kinase (MAPK) and phos-
phatidylinositol 3-kinase (PI3K) signaling [5-8]. However, 
very limited studies have shown the direct evidence of Smad 
signaling in mediated TGFβ-induced transdifferentiation of 
human fibroblasts to myofibroblasts [8,9].
Numerous literature reports suggest that HDAC inhibi-
tors can cause repression of TGFβ-induced profibrotic genes, 
including collagen (Col) type 1 and smooth muscle actin 
(αSMA) [10,11]. Additionally, it is also reported that HDAC 
inhibitors attenuate TGFβ-driven epithelial-to-mesenchymal 
transition (EMT) [12,13]. Recently, our laboratory demon-
strated that epigenetic modulation of corneal wound healing 
by histone deacetylase (HDAC) inhibitors is an innova-
tive approach to effectively treat corneal fibrosis without 
significant complications or side effects [14,15]. We found 
that HDAC inhibitors are selective and potent inhibitors of 
corneal fibrosis in rabbits in vivo, and that they attenuate 
TGFβ-induced profibrotic expression of genes in canine, 
equine, and human corneal fibroblasts in vitro [14-17]. 
Although several HDAC inhibitors are being investigated 
for their antifibrotic effects, vorinostat is the only HDAC 
inhibitor that is already FDA-approved for humans, and is 
currently in clinical use to treat cutaneous T-cell lymphoma. 
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Role of 5′TG3′-interacting factors (TGIFs) in Vorinostat (HDAC 
inhibitor)-mediated corneal fibrosis inhibition
Ajay Sharma,1,3 Nishant R. Sinha,3 Saad Siddiqui,3 Rajiv R. Mohan1,2,3
1Harry S. Truman Memorial Veteran Hospital, Columbia, MO; 2Mason Eye Institute, School of Medicine, Columbia, MO; 
3Veterinary Medicine and Surgery, University of Missouri, Columbia, MO
Purpose: We have previously reported that vorinostat, an FDA-approved, clinically used histone deacetylase (HDAC) 
inhibitor, attenuates corneal fibrosis in vivo in rabbits by blocking transforming growth factor β (TGFβ). The 5′TG3′-
interacting factors (TGIFs) are transcriptional repressors of TGFβ1 signaling via the Smad pathway. The present study 
was designed to explore the expression of TGIFs in human corneal fibroblasts and to investigate their role in mediating 
the antifibrotic effect of vorinostat.
Methods: Human corneal fibroblast cultures were generated from donor corneas. RNA isolation, cDNA preparation, and 
PCR were performed to detect the presence of TGIF1 and TGIF2 transcripts. The cultures were exposed to vorinostat 
(2.5 µM) to test its effect on TGIF mRNA and protein levels using qPCR and immunoblotting. Myofibroblast formation 
was induced with TGFβ1 (5 ng/ml) treatment under serum-free conditions. The changes in fibrosis parameters were 
quantified by measuring fibrosis marker α-smooth muscle actin (αSMA) mRNA and protein levels with qPCR, immu-
nostaining, and immunoblotting. Smad2/3/4 and TGIF knockdowns were performed using pre-validated RNAi/siRNAs 
and a commercially available transfection reagent.
Results: Human corneal fibroblasts showed the expression of TGIF1 and TGIF2. Vorinostat (2.5 µM) caused a 2.8–
3.3-fold increase in TGIF1 and TGIF2 mRNA levels and a 1.4–1.8-fold increase in TGIF1 and TGIF2 protein levels. 
Vorinostat treatment also caused a significant increase in acetylhistone H3 and acetylhistone H4. Vorinostat-induced 
increases in TGIF1 and TGIF2 were accompanied by a concurrent decrease in corneal fibrosis, as indicated by a decrease 
in αSMA mRNA by 83±7.7% and protein levels by 97±5%. The RNAi-mediated knockdown of Smad2, Smad3, and 
Smad4 markedly attenuated TGFβ1-evoked transdifferentiation of fibroblasts to myofibroblasts. The siRNA-mediated 
knockdown of TGIF1 and TGIF2 neutralized vorinostat-evoked decreases in αSMA mRNA by 31%–45% and protein 
levels by 12%–23%.
Conclusions: Human corneal fibroblasts demonstrate the expression of TGIF1 and TGIF2 transcription factors. These 
transcriptional repressors are critical, at least partially, in mediating the antifibrotic effect of vorinostat in the cornea.
Correspondence to: Rajiv R. Mohan, University of Missouri, 1600 
E. Rollins Rd, Columbia, MO 65211; Phone: (573) 884-1449; FAX: 
(573) 884-4100, email: mohanr@health.missouri.edu
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Previous studies from our laboratory have demonstrated that 
vorinostat can inhibit TGFβ-mediated transdifferentiation 
of cultured corneal fibroblasts to myofibroblasts and laser 
surgery-induced corneal scarring in rabbits [15-17]. Unlike 
other antifibrotic agents, vorinostat is relatively non-toxic 
and does not affect the viability or proliferation of corneal 
fibroblasts [15-17]. However, the mechanism mediating the 
antifibrotic effect of vorinostat in the cornea is not yet known.
The TGFβ–Smad pathway is modulated by a wide variety 
of Smad co-repressors, including c-Ski, SnoN, Smads6, 
Smad7, and 5′TG3′-interacting factors (TGIFs) [18-20]. 
Recently, TGIFs have gained more attention because of their 
role in cell proliferation and cell differentiation [21,22]. TGIFs 
are members of the three amino acid loop extension (TALE) 
class of homeodomain proteins and consist of two closely 
related transcription factors, TGIF1 and TGIF2. Both TGIF1 
and TGIF2 can cause repression of TGFβ1-activated genes by 
direct competition with the coactivator p300/CBP for Smad2 
interactions [23]. TGIF1 expression has been detected in few 
adult tissues, whereas TGIF2 was ubiquitously expressed 
in several adult human tissues [24-27]. The expression and 
role of TGIFs in the adult cornea is still unknown. In the 
present study, we tested the hypothesis that TGIF1 and TGIF2 
are expressed in human corneal fibroblasts, and that these 
proteins are involved in mediating the anti-fibrotic effects of 
vorinostat in the cornea using an in vitro model. Our results 
demonstrate that human corneal fibroblasts express TGIF1 
and TGIF2 transcription factors, and that upregulation of 
these transcriptional repressors contributes, at least partially, 
to the antifibrotic effect of vorinostat in the cornea.
METHODS
Human corneal fibroblast and myofibroblast cultures: 
Primary corneal fibroblast cultures were generated from 
donor human corneas procured from an eye bank (Heartland 
Eye Bank, Kansas City, MO). Based on the slit lamp, specular 
microscopy, physical examination, and donor medical record 
data provided by the eye bank, it was ensured that only 
healthy and disease-free corneas were used in the present 
study. Corneal tissues were washed with a sterile cell culture 
medium, and the epithelium and endothelium were removed 
by gentle scraping with a #15 scalpel blade. The corneal 
stroma was cut into small sections, placed on a culture dish, 
and incubated in a humidified 5% CO2 incubator at 37 °C 
in minimum essential medium (MEM) supplemented with 
10% fetal bovine serum for two to three weeks. The primary 
human corneal fibroblasts harvested from these corneal 
buttons were seeded in six-well plates in MEM supplemented 
with 10% fetal bovine serum and allowed to reach 60%–70% 
confluence. To generate myofibroblast cultures, the fibro-
blasts were seeded using MEM containing 10% fetal bovine 
serum, switched to serum-free medium containing TGFβ1 
(5 ng/ml) after 12 h, and incubated for 5 days. The cultures 
were fed with fresh serum-free TGFβ1-containing medium 
every 24 h.
Vorinostat, siRNA and RNAi treatment: A 10 mM stock solu-
tion of vorinostat (Cayman Chemical Company, Ann Arbor, 
MI) was prepared in dimethylsulfoxide (DMSO) and diluted 
with MEM to achieve a final concentration of 2.5 µM in the 
culture medium. The equivalent amount of DMSO (0.5 µl in 
2 ml culture medium) served as controls. For the knockdown 
of TGIF1 and TGIF2 gene expression, prevalidated siRNA 
(Ambion Life technologies, Grand Island, NY) were used 
at a 30 nM concentration (Table 1). For the knockdown of 
Smad2/3/4, the prevalidated RNA interference (RNAi) 
oiligos (Table 1) were cloned into a pcDNA 6.2 miR RNAi 
expression vector under the control of Pol II promoter (Life 
Technologies, Grand Island, NY). The siRNA and RNAi 
plasmid transfections were performed using the commer-
cially available transfection reagent lipofectamine3000 (Life 
technologies corporation, Grand Island, NY) as per the 
manufacturer’s instructions. Briefly, a transfection solution 
was prepared by adding 10 µl lipofectamine3000 in 200 µl 
of optiMEM medium to the appropriate amounts of siRNA/
RNAi plasmid in 200 µl of opitiMEM. The mixture was incu-
bated for 5 min at room temperature. The above transfection 
mixture was added to the human corneal fibroblasts in 1 ml 
of a serum-free culture medium.
RNA extraction and cDNA synthesis: Total RNA from cells 
was extracted with an RNeasy kit (Qiagen, Valencia, CA) and 
reverse transcribed to cDNA following the vendor’s instruc-
tions (Promega, Madison, WI). PCR was performed for the 
detection of TGIF1 and TGIF2. A 50 µl reaction mixture 
containing 2 µl cDNA, 2 µl forward (200 nM) and 2 µl 
reverse (200 nM) primer, 0.2 mM of each deoxynucleotide 
triphosphates (dNTP), and 1.25 U of Taq polymerase was 
run one cycle at 95 °C for 3 min, then 40 cycles of 95 °C 
for 30 s, followed by 55 °C for 30 s and 72 °C for 60 s, using 
a thermocycler (Bio-Rad Laboratories, Hercules, CA) and 
primers listed in Table 2. The cDNA samples were prepared 
from fibroblasts originating from two different human donor 
corneas. Each PCR was repeated at least three times.
Gene expression quantification by qPCR: The relative 
quantification of TGIFs mRNA was performed using the 
StepOne Plus real-time PCR system (Applied Biosystems, 
Carlsbad, CA). A 20 µl reaction mixture containing 2 µl 
of cDNA, 2 µl of forward primer (200 nM), 2 µl of reverse 
primer (200 nM), and 10 µl of 2X SYBR green super mix 
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(Bio-Rad Laboratories, Hercules, CA) was run at a universal 
cycle (95 °C for 10 min, 40 cycles at 95 °C for 15 s, and 60 °C 
for 60 s) in accordance with the manufacturer’s instructions, 
using primers listed in Table 2.
Immunoblotting: Both the treated and untreated HCF cultures 
were lysed in a radioimmunoprecipitation assay (RIPA) lysis 
buffer containing a protease inhibitor cocktail (Santa Cruz 
Biotechnology, Santa Cruz, CA) followed by centrifugation 
at 10,000 g for 10 min. Samples were suspended in a NuPAGE 
LDS buffer containing a reducing agent (Life Technologies 
Corporation, Grand Island, NY) and heated at 70 °C for 
10 min. Protein samples were resolved by NuPAGE Novex 
Bis-Tris mini gels (Invitrogen) and transferred onto the 
polyvinylidene difluoride membranes using wet transfer at 
25 V. The transferred proteins were detected by incubating 
the membrane with primary antibodies: TGIF1, TGIF2 (Santa 
Cruz Biotechnology, Santa Cruz, CA), acetylhistone H3, 
acetyl histone H4 (EMD Millipore, Billerica, MA), alpha 
smooth muscle actin (αSMA Dako, Carpinteria, CA), and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Santa 
Cruz Biotechnology), followed by alkaline phosphatase 
conjugated anti-mouse, anti-goat, or anti-rabbit secondary 
antibody. After washing three times in 0.05% Tween-20 in 
Tris-buffered saline of pH 8.0 for 5 min each, the blot was 
developed using the nitroblue tetrazolium/5-bromo-4-chloro-
3-indolylphosphate method. Three separate western blots 
were performed for each experiment. The digital quantifi-
cation of western blots was performed using NIH Image J 
software.
Immunofluorescence: Cells were fixed with 4% paraformal-
dehyde, and immunofluorescence staining for α–smooth 
muscle actin (1:200 dilution) and acetyl histone H3 (1:100 
dilution EMD Millipore, Billerica, MA) was performed. 
Samples were incubated with 5% BSA for 30 min at room 
Table 1. NucleoTide sequeNces of Two validaTed RNai aNd siRNa oligos used iN The sTudy.
Smad2 RNAi-1 validated (5′ to 3′) GAGCAGAACCTCTCTGAATTTGGTTTTGGCCACTGACTGAC-
CAAATTCAGAGGTTCTGCT
Smad2 RNAi-2 validated (5′ to 3′) GTGTAAAGGCCTGTTGTATCCCGTTTTGGCCACTGACTGAC-
GGGATACAAGGCCTTTACA
Smad3 RNAi-1 validated (5′ to 3′) GCACTGAGGCACTCTGCGAAGAGTTTTGGCCACTGACT-
GACTCTTCGCAGTGCCTCAGTG
Smad3 RNAi-2 validated (5′ to 3′) GTTCATCTGGTGGTCACTGGTTGTTTTGGCCACTGACTGACAAC-
CAGTGCACCAGATGAA
Smad4 RNAi-1 validated (5′ to 3′) GTATGATGGTAAGTAGCTGGCTGTTTTGGCCACTGACTGACAGC-
CAGCTTTACCATCATA
Smad4 RNAi-2 validated (5′ to 3′) GTTTCCGACCAGCCACCTGAAGGTTTTGGCCACTGACT-
GACCTTCAGGTCTGGTCGGAAA
TGIF1 siRNA-1 validated (5′ to 3′) GCAUGGACAUUCCCUUGGATT
TGIF1 siRNA-2 validated (5′ to 3′) GCACCGUUACAAUGCCUAUTT
TGIF2 siRNA-1 validated (5′ to 3′) GCCUCCUAGCUGGGAUUGUTT
TGIF2 siRNA-2 validated (5′ to 3′) GGACGACAGCCUUUAGUUUTT
Table 2. sequeNces of pRimeRs used iN The sTudy.
Gene Forward (5′ to 3′) Reverse (5′ to 3′) Accession Number
For Real Time PCR
Smooth muscle actin TGGGTGACGAAGCACAGAGC CTTCAGGGGCAACACGAAGC NM_001613
TGIF1 CTGTGTTTCGAGGATGGTTC CATGGAAAGGAATCAGAGCC NM_170695
TGIF2 CCTGTCAGTGCTGCAAAT GGCGGGAAATGGTAAACT NM_021809.5
β-actin CGGCTACAGCTTCACCACCA CGGGCAGCTCGTAGCTCTTC NM_007393.4
For PCR
TGIF1 GACATTCCCTTGGACCTTTCT GACCACTCTGTGTATTCGTACTT NM_170695
TGIF2 GGCACCTAGCAGAGAAA-
GATAAG
GGGAGGCTGAGGCAAATAAT NM_021809.5
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temperature, followed by primary antibody incubation for 90 
min. The secondary antibodies Alexa 488 donkey anti-rabbit 
and Alexa 594 donkey anti-mouse IgG secondary antibody 
(1:500 dilution) were incubated for 1 h. The cells were washed 
three times in PBS buffer, mounted in Vectashield containing 
4'-6-diamidino-2-phenylindole (DAPI; Vector Laboratories), 
and viewed and photographed with a Leica fluorescent micro-
scope (Leica DM 4000B) equipped with a digital camera 
(SpotCam RT KE).
Statistical analyses: Results were expressed as a mean ± stan-
dard error. Statistical analysis was performed using one-way 
ANOVA and Tukey’s test. A value of p<0.05 was considered 
significant.
RESULTS
Detection of TGIF1 and TGIF2 in human corneal fibroblasts: 
To investigate whether human corneal fibroblasts express 
TGIFs, PCR was performed to detect the presence from 
mRNA transcripts for TGIF1 and TGIF2. Figure 1 shows 
the agarose gel electrophoresis of the PCR demonstrating 
the presence of amplified bands for TGIF1 and TGIF2 in the 
cDNA obtained from human corneal fibroblasts. An appro-
priately sized amplification product of 608 bp was detected 
for TGIF1 in two cDNA samples of human corneal fibroblasts 
originating from two separate donor human corneas. Ampli-
fication products for TGIF2 corresponding to the product size 
of 646 bp were also present in the human corneal fibroblast 
cDNA samples. No PCR product was detected in the nega-
tive controls that contained primers for TGIFs but no cDNA 
(Figure 1).
Effect of vorinostat on TGIF1 and TGIF2 expression and 
histone acetylation: After confirming that human corneal 
fibroblasts express TGIF1 and TGIF2, we next tested if 
vorinostat treatment of human corneal fibroblasts increased 
TGIF expression. The mRNA and protein lysates were 
obtained from the human corneal fibroblasts +/− vorinostat. 
As is evident from Figure 2A, treatment of human corneal 
fibroblasts with vorinostat (2.5 µM) caused a 2.8±0.81-
fold increase (p<0.05) in TGIF1 mRNA and 3.3±0.25-fold 
increase (p<0.01) in TGIF2 mRNA levels as compared 
to DMSO-treated vehicle control groups (–vorinostat). 
Figure 2B shows the western blot detection of TGIF protein 
levels in DMSO-treated vehicle control and vorinostat 
(2.5 µM)-exposed human corneal fibroblasts. The immunob-
lotting data demonstrated that vorinostat caused a 1.4-fold 
increase (p<0.05) in TGIF1 and 1.8-fold increase (p<0.05) 
in TGIF2 protein in comparison to vehicle-treated control 
human corneal fibroblasts. Further, we also tested the effect 
of vorinostat on TGIF1 and TGIF2 expression in corneal 
keratocytes. The corneal keratocytes were isolated using 
dispase and collagenase enzymatic digestions and grown in 
serum-free medium in the presence or absence of vorinostat. 
Our results demonstrate that vorinostat increased the TGIF1 
and TGIF2 mRNA in human corneal keratocytes as observed 
in human corneal fibroblasts (data not shown).
We further postulated that the observed increase in 
TGIFs was likely mediated by enhanced transcription due 
to histone acetylation and DNA unfolding caused by vori-
nostat. To test whether the 2.5 µM dose of vorinostat used 
in the present study was sufficient to cause histone acetyla-
tion, we performed immunoblotting for acetylated histone 
H3 and acetylated histone H4. As can be seen in Figure 3A, 
vorinostat treatment of human corneal fibroblasts caused 
an 8-fold increase (p<0.001) in acetylhistone H3 and a 
50-fold increase (p<0.001) in acetylhistone H4. Figure 3B 
demonstrated that only 36±4% of nuclei stained +ve for 
acetylhistone H3 in DMSO-treated vehicle control corneal 
Figure 1. Agarose gel electropho-
resis of PCR showing the detec-
tion of TGIF1 and TGIF2 mRNA 
expression in human corneal 
fibroblasts. Appropriately sized 
PCR amplification products for 
TGIF1 and TGIF2 were detected 
in two independent cDNA samples 
(S1 and S2) of corneal fibroblasts 
prepared from two separate human 
donor corneas. The lower level of 
TGIF detected in sample S2 is due 
to a smaller amount of starting cDNA in the PCR reaction. -ve denotes negative controls that contained TGIF1 and TGIF2 primers but water 
instead of cDNA. L denotes a 100-base-pair DNA ladder.
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fibroblasts (–vorinostat). On the other hand, vorinostat treat-
ment of human corneal fibroblasts significantly increased the 
acetylhistone H3 to 75±3.4% (p<0.001) nuclei showing +ve 
staining. A similar trend demonstrating the increase in acetyl-
histone H4-stained nuclei was also observed with vorinostat 
(data not shown). No statistically significant difference in the 
total number of DAPI-stained nuclei (blue) was observed in 
the control and vorinostat-exposed human corneal fibroblasts 
(Figure 3B).
Effect of Smad knockdown on TGFβ1-induced myofibroblasts 
formation: TGIFs are negative regulators of TGFβ1-mediated 
Smad signaling. Therefore, we next tested the hypothesis that 
TGFβ1-mediated transdifferentiation of human corneal fibro-
blasts to myofibroblasts is largely mediated through Smad 
signaling. To test this hypothesis, we transfected the human 
corneal fibroblasts with plasmids expressing Smad2/Smad3 
or Smad4 RNAi. Figure 4 shows the effect of RNAi-mediated 
knockdown of Smad2/Smad3 or Smad4 on TGFβ1-evoked 
SMA formation. As is evident from Figure 4, the knockdown 
of Smad2/Smad3 or Smad4 markedly attenuated TGFβ1-
mediated increase in αSMA in cultured human corneal 
fibroblasts tested using immunofluorescence (Figure 4A-E) 
and immunoblotting (Figure 4F). This suggests that TGFβ1-
mediated transdifferentiation of human corneal fibroblasts to 
myofibroblasts is largely mediated through Smad signaling.
Effect of vorinostat on myofibroblast formation: Next, we 
tested the hypothesis that vorinostat-induced increases 
in TGIF1 and TGIF2 were accompanied by a concurrent 
decrease in corneal fibrosis. An in vitro model of corneal 
fibrosis in which the application of TGFβ1 induces myofibro-
blasts formation was used to test this hypothesis. The trans-
formation of corneal fibroblasts to myofibroblasts is a key 
pathological feature in corneal fibrosis. Myofibroblasts are 
contractile, metabolically active, and opaque cells containing 
intracellular microfilament bundles of αSMA, which serves as 
a maker for fibrosis. As expected, TGFβ1treatment of human 
corneal fibroblasts caused a 3.8±0.2-fold increase (p<0.001) 
in αSMA mRNA (Figure 5A) and a 4.3-fold increase (p<0.01) 
in SMA protein (Figure 5B). Vorinostat treatment signifi-
cantly attenuated TGFβ 1-induced increases in αSMA mRNA 
by 83±7.7% (p<0.001, Figure 5A) and protein levels by 97±5% 
(p<0.001, Figure 5B).
The antifibrotic effects of vorinostat were further 
investigated by αSMA immuno-cytochemistry (Figure 6). 
As anticipated, human corneal fibroblasts cultured in the 
absence of TGFβ1 (–TGFβ) under serum-free conditions 
showed minimal αSMA expression (Figure 6). TGFβ1 (5 ng/
ml) treatment caused a robust myofibroblast formation, as 
indicated by an intense αSMA immunostaining in 82%–94% 
of cells (p<0.001). Following vorinostat treatment, only 
6%–8% of cells (p<0.001) showed αSMA immunostaining, 
confirming that vorinostat remarkably attenuates TGFβ1-
evoked myofibroblast formation (Figure 6).
Effect of TGIFs knockdown on the antifibrotic effect of 
vorinostat: Finally, we tested whether the increase in TGIF 
expression is an essential step for the antifibrotic effect of 
vorinostat. If so, then the TGIF knockdown should impede 
the antifibrotic effect of vorinostat. To test this hypothesis, 
we designed a reverse experiment wherein we tested the 
antifibrotic effect of vorinostat along with siRNA-mediated 
knockdown of TGIFs. Figures 5A and B show that TGIF1 and 
TGIF2 knockdown prevented vorinostat-mediated decreases 
in αSMA mRNA by 31%–45% (p<0.05) and protein levels by 
12%–23% (p<0.05), respectively. Similarly, immunostaining 
data for αSMA shows that TGIF1 or TGIF2 siRNA knock-
down significantly prevented vorinostat-induced decreases 
Figure 2. Quantitative real-time 
PCR and immunoblotting demon-
strating the effect of vorinostat (2.5 
µM) on TGIF1 and TGIF2 mRNA 
and protein levels. A significant 
increase in TGIF1 and TGIF2 
mRNA (A) and protein (B) levels 
is evident after vorinostat treat-
ment (+vorinostat) as compared 
to DMSO-treated vehicle controls 
(–vorinostat). * p<0.05, # p<0.01 
compared to vorinostat.
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in myofibroblast formation. Only 6%–8% of cells (p<0.05) 
showed αSMA immunostaining when exposed to vorinostat 
alone, whereas 12%–18% of cells (p<0.05) stained for αSMA 
when cells were exposed to vorinostat after either TGIF1 or 
TGIF2 knockdown (Figure 6). Overall, our data suggest that 
the knockdown of either TGIF1 or TGIF2 partially blocks the 
antifibrotic effect of vorinostat.
To test whether the simultaneous knockdown of both 
TGIF1 and TGIF2 had any additive or synergistic effect on 
blocking the antifibrotic effect of vorinostat, we treated the 
cells with siRNA of both TGIF1 and TGIF2. However, the 
simultaneous knockdown of TGIF1 and TGIF2 did not cause 
any additive neutralization of vorinostat on αSMA mRNA 
(Figure 5A) or protein (Figure 5B and Figure 6) as compared 
to the knockdown of either the TGIF1 or TGIF2 alone.
DISCUSSION
TGIFs belong to the three-amino acid loop extension (TALE) 
family of homeodomain proteins consisting of two transcrip-
tion factors, TGIF1 and its closely related paralog TGIF2. 
TGIFs are highly expressed during mammalian embryonic 
development and have been shown to play a critical role in 
the development of many organs, including the eyes [28-30]. 
However, after birth, TGIF expression sharply declines, with 
only a handful of tissues showing detectable levels of TGIFs 
in adult animals [25,27]. In the present study, we demonstrate 
that human corneal fibroblasts express both TGIF1 and 
TGIF2. A literature survey reveals that very limited informa-
tion is available concerning the biologic functions of TGIFs in 
fully differentiated adult tissues. Therefore, our data open up 
Figure 3. Representative immu-
noblotting and immunof luores-
cence images showing the effect 
of vorinostat (2.5 µM) on histone 
acetylat ion. Immunoblot t ing 
image and the quantif ication 
graph (A) showing that vorinostat 
(+vorinostat) caused eight fold and 
50 fold (Ψ p<0.001) increase in 
acetylhistone H3 and acetylhistone 
H4 protein levels in comparison 
to DMSO-treated vehicle controls 
(–vorinostat). Immunofluorescence 
images (B) show significantly 
more nuclei (p<0.001) stained +ve 
for acetylhistone H3 (Green) in 
vorinostat-exposed human corneal 
fibroblast cultures (+vorinostat) as 
compared to non-treated controls 
(–vorinostat). The DAPI-staining 
(blue) depicts that there was no 
significant difference in the total 
number of nuclei between control 
and vorinostat-treated cultures. 
Scale bar=100 μm.
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the exciting possibility of investigating the biologic functions 
of these transcription factors in the corneal tissue.
HDACs are a group of enzymes that deacetylate histone 
and non-histone proteins and are critically involved in the 
epigenetic regulation of gene transcription, cellular prolifera-
tion, survival, and differentiation [31-33]. Given their critical 
role in modulating cell cycles, HDACs have been extensively 
studied in cancer biology. In addition, the role of HDACs and 
epigenetic modulation has been implicated in many other 
diseases, including fibrosis, autoimmune, inflammatory, 
and metabolic diseases processes [34-40]. This has led to 
the testing of a variety of HDAC inhibitors to treat fibrotic 
diseases, inflammatory bowel diseases, multiple sclerosis, 
and systemic lupus erythematosus [34-40]. Our laboratory has 
recently demonstrated that the HDAC inhibitor trichostatin 
A and its FDA-approved derivative, vorinostat, effectively 
Figure 4. Representative immunofluorescence images and immunoblotting showing the effect of RNAi-mediated Smad2/3/4 knockdown 
on αSMA. Control human corneal fibroblast cultures (–TGFβ) showed no αSMA staining (A) or protein levels (F). Cultures treated with 
TGFβ1 (5 ng/ml) showed robust αSMA staining (B) and protein levels (F). The knockdown of Smad2 (C, F)/Smad3 (D, F)/Smad4 (E, F) 
markedly blocked TGFβ-evoked increase in αSMA.
Figure 5. Quantitative real-time 
PCR and immunoblotting showing 
the effect of vorinostat (2.5 
µM), TGIF1, and TGIF2 siRNA 
knockdown on αSMA protein 
levels. Control human corneal 
fibroblast cultures (–TGFβ) showed 
no αSMA expression. Cultures 
treated with TGFβ1 (5 ng/ml) 
showed robust αSMA increase. 
Vorinostat (+TGFβ+vorinostat) 
treatment markedly attenuated 
TGFβ-evoked αSMA mRNA (A) and protein (B) expression. The knockdown of TGIF1 (+TGFβ+vorinostat+TGIF1siRNA) and TGIF2 alone 
(+TGFβ+vorinostat+TGIF2siRNA) or in combination (+TGFβ+vorinostat+TGIF1+2siRNA) significantly reversed the effect of vorinostat on 
αSMA. * p<0.001 compared to –TGFβ, Ψ p<0.001 compared to +TGFβ, # p<0.05 compared to +TGFβ+vorinostat.
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reduce corneal fibrosis primarily through the inhibition of 
TGFβ effects [14-17]. Precisely how HDAC inhibitors block 
the biologic effects of TGFβ is not known. TGIFs are known 
transcriptional repressors of TGFβ-mediated Smad signaling, 
and our RNAi data suggest that TGFβ-driven transdifferentia-
tion of human corneal fibroblasts to myofibroblasts is largely 
mediated through Smad signaling. TGIFs have been shown 
to directly associate with Smad2/3 and inhibit TGFβ-driven 
profibrotic gene expression [23]. Therefore, we postulated 
that HDAC inhibitors attenuate corneal fibrosis by increasing 
TGIFs. Indeed, the detection of significantly increased levels 
of TGIF mRNA and protein in vorinostat-treated human 
corneal fibroblasts not only supports our hypothesis but also 
provides the evidence that TGIF levels can be potentially 
altered in the adult human cornea through pharmacological 
manipulation. Furthermore, vorinostat-induced increases 
in TGIFs were concurrently accompanied by a remarkable 
increase in the acetylation of histones H3 and H4, which is a 
well-known effect of HDAC inhibitors. Histone acetylation 
increases DNA transcriptional activity, and may explain the 
increased transcriptional levels of TGIFs in human corneal 
fibroblasts following vorinostat treatment. Next, we reasoned 
that, if increased TGIF expression is an essential step for the 
antifibrotic effect of vorinostat, then the drug should lose 
its antifibrotic effect without TGIFs. To test this hypothesis, 
we used siRNAs to knockdown TGIFs. We observed that 
vorinostat showed a significantly diminished antifibrotic 
effect, as indicated by increased αSMA when either TGIF1 
or TGIF2 was knocked down. These results suggest that 
TGIFs are vital for the antifibrotic effect of vorinostat in the 
cornea. However, it is worthwhile to point out that only a 
partial reversal of the antifibrotic effect of vorinostat was 
achieved by knocking down the TGIFs. Multiple factors can 
account for this observed partial reversal. TGIFs are short-
lived proteins and undergo rapid synthesis and degradation 
[41]. Therefore, the noted partial reversal of vorinostat effects 
could be due to the quick de novo synthesis of TGIFs that 
can partially counterbalance the siRNA knockdown. Alter-
natively, vorinostat may have caused a concurrent increase 
in the transcription levels of other know TGFβ co-repressors, 
Figure 6. Representative immuno-
fluorescence images and the quan-
tification graph showing the effect 
of vorinostat (2.5 µM), TGIF1, 
and TGIF2 siRNA knockdown on 
αSMA. Control human corneal 
fibroblast cultures (-TGFβ) showed 
no αSMA staining. Cultures 
treated with TGFβ1 (5 ng/ml) 
showed a robust αSMA staining. 
Vorinostat treatment markedly 
attenuated TGFβ-evoked αSMA 
staining. The knockdown of TGIF1 
(+TGFβ+vorinostat+TGIF1siRNA) 
a n d  T G I F 2  a l o n e 
(+TGFβ+vorinostat+TGIF2siRNA) 
or in combinat ion (+TGFβ 
+vorinostat +TGIF1 +2siRNA) 
markedly blocked the effect 
of vorinostat on αSMA. Scale 
bar=100 μm. * p<0.001 compared 
to –TGFβ, Ψ p<0.001 compared 
to +TGFβ, # p<0.05 compared to 
+TGFβ+vorinostat.
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such as c-Ski, SnoN, Smad6, and Smad7 [18-20], and in that 
case, the selective knockdown of only TGIFs will merely 
partially reverse the antifibrotic effects of vorinostat. Future 
studies will test the role of other TGFβ co-repressors in 
modulating the antifibrotic effect of vorinostat.
In conclusion, we demonstrate that human corneal fibro-
blasts express TGIF1 and TGIF2 transcription factors. These 
transcriptional repressors are critical, at least partially, in 
mediating the antifibrotic effect of vorinostat in the cornea 
(Figure 7).
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